Performance and Safety of the Extravascular Implantable Cardioverter Defibrillator Through Long-Term Follow-Up: Final Results From the Pivotal Study
Authors:
- Paul FriedmanPFPaul Friedman
- Francis MurgatroydFMFrancis Murgatroyd
- Lucas V.A. BoersmaLBLucas V.A. Boersma
- Jaimie ManlucuJMJaimie Manlucu
- Bradley P. KnightBKBradley P. Knight
- Nicolas ClémentyNCNicolas Clémenty
- Christophe LeclercqCLChristophe Leclercq
- Anish AminAAAnish Amin
- Béla MerkelyBMBéla Merkely
- Ulrika Maria Birgersdotter-GreenUBUlrika Maria Birgersdotter-Green
- Joseph Yat Sun ChanJCJoseph Yat Sun Chan
- Mauro BiffiMauro Biffi
Top Cited Papers
Open Access
- 28 January 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (4) , 322-332
Abstract
BACKGROUND: Substernal lead placement of the extravascular implantable cardioverter defibrillator (EV ICD) permits both defibrillation at thresholds similar to those seen with transvenous implantable cardioverter defibrillators and effective anti-tachycardia pacing (ATP) while avoiding the vasculature and associated complications. The global Pivotal study has shown the EV ICD system to be safe and effective through 6 months, but long-term experience has yet to be published. Our aim was to report the performance and safety of the EV ICD system throughout the study. METHODS: The EV ICD Pivotal study was a prospective, global, single-arm, premarket clinical study. Individuals with a Class I or IIa indication for a single-chamber implantable cardioverter defibrillator per guidelines were enrolled. Freedom from major system- or procedure-related complications and appropriate and inappropriate therapy rates were assessed through 3 years with the Kaplan-Meier method. ATP success was calculated from simple proportions. RESULTS: An implantation was attempted in 316 patients (25.3% female; 53.8±13.1 years of age; 81.6% primary prevention; left ventricular ejection fraction, 38.9±15.4%). Of 299 patients with a successful implantation, 24 experienced 82 spontaneous arrhythmic episodes that were appropriately treated with ATP only (38, 46.3%), shock only (34, 41.5%), or both (10, 12.2%) for a Kaplan-Meier–estimated rate of first any appropriate therapy of 9.2% at 3 years. ATP was successful in 77.1% (37/48) of episodes, and ATP use significantly increased from discharge to last follow-up visit ( P <0.0001). Shock therapy was successful in 100% (27/27) of discrete, spontaneous ventricular arrhythmias. The inappropriate shock rates at 1 and 3 years were 9.8% and 17.5%, respectively, with P-wave oversensing the predominant cause. No major intraprocedural complications were reported, and the estimated freedom from system- or procedure-related major complications was 91.9% at 1 year and 89.0% at 3 years. The most common major complications were lead dislodgement (10 events; n=9 patients, 2.8%), postoperative wound or device pocket infection (n=8, 2.5%), and device inappropriate shock delivery (n=4, 1.3%). Twenty-four system revisions were performed as a result of major complications related to the EV ICD system or procedure. CONCLUSIONS: From implantation to study completion, the EV ICD Pivotal study demonstrated that a single integrated system with an extravascular lead placed in the substernal space maintains high ATP success, effective defibrillation, and a consistent safety profile. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04060680.Keywords
This publication has 32 references indexed in Scilit:
- Fifteen years of subcutaneous implantable cardioverter-defibrillator therapy: Where do we stand, and what will the future hold?Heart Rhythm, 2024
- Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator SystemJACC, 2023
- Antitachycardia pacing success in implantable cardioverter-defibrillators by patient, device, and programming characteristicsHeart Rhythm, 2022
- Comparative Assessment of Transvenous versus Subcutaneous Implantable Cardioverter-defibrillator Therapy Outcomes: An Updated Systematic Review and Meta-analysisInternational Journal of Cardiology, 2022
- First-in-Human Chronic Implant Experience of the Substernal Extravascular Implantable Cardioverter-DefibrillatorJACC: Clinical Electrophysiology, 2020
- Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocksHeart Rhythm, 2020
- 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive SummaryJACC, 2018
- Venous Obstruction in Cardiac Rhythm Device TherapyCurrent Treatment Options in Cardiovascular Medicine, 2018
- Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator RegistryJACC, 2017
- Acute Lead Dislodgements and In-Hospital Mortality in Patients Enrolled in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator RegistryJACC, 2010